

UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2001

(Rupees in million)

	Quater Ended		Half year Ended		Year Ended 31.03.2001 (Audited)
	30.09.2001	30.09.2000	30.09.2001	30.09.2000	
1. Net Sales	3370.4	2696.6	6349.3	5114.5	10475.1
2. Other Income	119.4	100.0	180.6	175.8	386.1
3. Total Expenditure					
a) (Increase)/ decrease in Stock-in -trade	100.9	(191.1)	(46.6)	(177.6)	(375.8)
b) Consumption of Materials	1468.3	1336.5	3006.0	2490.4	5236.6
c) Staff Cost	149.2	121.4	303.4	237.6	499.0
d) Other Expenditure	934.9	796.2	1796.6	1441.9	2961.1
4. Interest	4.7	1.3	7.2	5.3	8.3
5. Depreciation	47.5	45.0	95.0	82.5	156.3
6. Profit (+) / Loss (-) before Tax (1+2-3-4-5)	784.3	687.3	1368.3	1210.2	2375.7
7. Provision for Taxation	*180.0	170.0	*320.0	305.5	585.0
8. Net Profit (+) / Loss (-) (6-7)	604.3	517.3	1048.3	905.2	1790.7
9. Paid-up Equity Share Capital	599.7	599.7	599.7	599.7	599.7
10. Reserves excluding Revaluation Reserves (as per balance-sheet of previous accounting year)	-	-	-	-	6540.5
11. Earning per Share ** Not Annualised	**10.07	**8.63		**15.09	29.86
12. Aggregate of Non- Promoter Shareholding - Number of Shares- Percentage of Shareholding	36541209 60.93	36490209 60.85	36541209 60.93	36490209 60.85	36505209 60.87

Notes :

- The above results were taken on record at the meeting of the Board of Directors held on 20th October, 2001.
- *Provision for tax includes deferred taxation .
- The Company is exclusively in the pharmaceutical business segment. The capital employed as on 30th September, 2001 was Rs.6317.6 million.

By order of the Board
For CIPLA LIMITED

Mumbai
20th October, 2001

Dr. Y. K. Hamied
Chairman & Managing Director